|
Tissueid
|
Age
|
Sex
|
Stage
|
Cell*
|
Diff#
|
Grade+
|
Status
|
TTLF
|
|---|
|
Lu1031
|
57
|
Female
|
IA
|
AD
|
Well
|
II
|
0
|
8.59
|
|
Lu1050
|
58
|
Male
|
IB
|
AD
|
Well
|
II
|
0
|
7.54
|
|
Lu1068
|
57
|
Female
|
IB
|
AD
|
Mod
|
III
|
1
|
3.28
|
|
Lu106
|
63
|
Male
|
IB
|
AD
|
Well
|
II
|
0
|
11.96
|
|
Lu113
|
89
|
Female
|
IA
|
AD
|
Well
|
II
|
1
|
5.68
|
|
Lu1182
|
61
|
Female
|
IA
|
BAC
|
Well
|
II
|
0
|
8.24
|
|
Lu1321
|
68
|
Female
|
IB
|
AD
|
Well
|
II
|
0
|
6.75
|
|
Lu1377
|
64
|
Female
|
IA
|
AD
|
Well
|
II
|
0
|
0.36
|
|
Lu1405
|
54
|
Female
|
IB
|
AD
|
Mod
|
III
|
0
|
8.03
|
|
Lu1450
|
74
|
Female
|
IB
|
AD
|
Well
|
II
|
0
|
8.08
|
|
Lu1479
|
64
|
Female
|
IA
|
AD
|
Well
|
II
|
0
|
8.08
|
|
Lu1518
|
55
|
Female
|
IB
|
AD
|
Mod
|
III
|
0
|
8.01
|
|
Lu1606
|
88
|
Female
|
IA
|
AD
|
Well
|
II
|
0
|
6.75
|
|
Lu1659
|
71
|
Female
|
IA
|
AD
|
Well
|
II
|
1
|
4.09
|
|
Lu1682
|
74
|
Female
|
IA
|
AD
|
Well
|
II
|
1
|
3.60
|
|
Lu1790
|
73
|
Female
|
IB
|
AD
|
Well
|
II
|
0
|
6.20
|
|
Lu1821
|
32
|
Male
|
IB
|
AD
|
Mod
|
III
|
0
|
6.47
|
|
Lu1848
|
46
|
Female
|
IB
|
AD
|
Well
|
II
|
0
|
5.29
|
|
Lu1942
|
70
|
Male
|
IB
|
AD
|
Mod
|
III
|
1
|
1.38
|
|
Lu1943
|
82
|
Female
|
IB
|
AD
|
Well
|
II
|
1
|
5.99
|
|
Lu2029
|
58
|
Female
|
IB
|
AD
|
Well
|
II
|
0
|
6.46
|
|
Lu2040
|
79
|
Female
|
IB
|
AD
|
Mod
|
III
|
0
|
0.78
|
|
Lu2368
|
58
|
Female
|
IB
|
AD
|
Mod
|
III
|
1
|
2.98
|
|
Lu2499
|
74
|
Female
|
IB
|
BAC
|
Well
|
I
|
0
|
5.03
|
|
Lu2502
|
77
|
Female
|
IA
|
BAC
|
Well
|
II
|
0
|
5.13
|
|
Lu346
|
67
|
Female
|
IA
|
AD
|
Well
|
II
|
0
|
5.08
|
|
Lu587
|
72
|
Female
|
IB
|
BAC
|
Well
|
I
|
0
|
5.85
|
- *Tumor cell subtype. AD-adenocarcinoma, BAC-bronchioalveolar carcinoma (adenocarcinoma in situ according to 2011I ASLC/ATS/ERS classification). +Grade – Mayo 4 level grade of differentiation. #Diff – summarized tumor degree of differentiation from grade. I-II well, III- moderate, IV – Poorly/undifferentiated. TTLF – time to last follow up in years; status – 1 death, 0 alive.
